中等度から重度のアトピー性皮膚炎の日本人患者におけるトラロキヌマブと外用コルチコステロイドの併用

基本情報

NCT ID: NCT04587453
ステータス: 完了
試験のフェーズ: 第3相
試験タイプ: 介入
目標被験者数: 106
治験依頼者名: LEO Pharma

概要

Primary objective: To evaluate the efficacy of tralokinumab in combination with topical corticosteroids (TCS) compared with placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD). Secondary objectives: To evaluate the efficacy of tralokinumab in combination with TCS on severity and extent of AD, itch, health-related quality of life, and health care resource utilisation compared with placebo in combination with TCS. To assess the safety of tralokinumab in combination with TCS when used to treat moderate-to-severe AD for 16 weeks.

対象疾患

Atopic Dermatitis

介入

Tralokinumab(DRUG)

Placebo(DRUG)

Topical corticosteroids (TCS)(OTHER)

依頼者（Sponsor）

Leo(INDUSTRY)